Abstract 116P
Background
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. The prognostic role of Fibrous sheath interacting protein 1 (FSIP1) in LUAD remains unclear. Thus, this study aims to identify and validate the prognostic value of FSIP1 in LUAD and explore its molecular functions.
Methods
Single-cell RNA sequencing (scRNA-seq) data of LUAD patients were collected from Gene Expression Omnibus (GEO) database, the major cell types were identified based on known markers. Additionally, the expression of FSIP1 was detected in 180 LUAD samples, Kaplan-Meier (KM) analysis of high- and low-expression patients was conducted. Univariate and multivariate Cox regression analyses were utilized to assess the prognostic ability of FSIP1. Then, FSIP1-silenced human LUAD cell lines were constructed, and the functions of FSIP1 were explored. Finally, immune infiltration analysis was performed in LUAD patients.
Results
In this study, we identified LUAD FSIP1+ cancer cells by using scRNA-seq data from GEO database. Additionally, we investigated the protein level and prognostic value of FSIP1 in 98 LUAD patients using Tissue Microarray. Compared with the adjacent, FSIP1 was higher expressed in LUAD tissues. KM analysis revealed that the 5-year OS rate to be 30% to 59% (FSIP1High vs FSIP1Low) in Tissue Microarray. Univariate and multivariate COX regression showed that FSIP1 should be an independent factor in poor prognosis. The receiver operating characteristic curve (ROC) and time-ROC curve both indicated that FSIP1 had a good performance in prognostic model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that FSIP1 was associated with migration. Migration assay and Western blotting showed that FSIP1 influenced cell migration and PI3K/AKT pathway. FSIP1 could influence the immune cell infiltration in lung adenocarcinoma patients.
Conclusions
This study verified that FSIP1 could serve as a valuable prognostic biomarker in LUAD and analyzed its impact on the disease and its association with the immune infiltration. The findings of this research provide valuable insights into the understanding of LUAD and could potentially lead to the development of new treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Unveiling a novel EpCAM-CD24+ circulating cells with unidentified origin associated with breast cancer distant metastasis
Presenter: Evgeniya Grigoryeva
Session: Poster session 08
174P - Prognostic value of the immune and metabolic profile in the response to neoadjuvant treatment with ICIs in triple-negative breast cancer patients (TNBC)
Presenter: Lucía Serrano García
Session: Poster session 08
175P - Utility of artificial intelligence (AI) in Ki67 scoring of a breast cancer (BC) patient population
Presenter: Xavier Pichon
Session: Poster session 08
176P - ERBB2 amplifications across sex, race, and cancer types
Presenter: Marc Machaalani
Session: Poster session 08
177P - HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms
Presenter: Wentao Yang
Session: Poster session 08
178P - PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease
Presenter: Federica Miglietta
Session: Poster session 08
179P - Multimodal deep learning integrating MRI and molecular profiles for predicting outcomes in triple-negative breast cancer
Presenter: Seong Hwan Park
Session: Poster session 08
181P - Molecular characterization and immune microenvironment analysis of MSI-H patients with or without MMR gene mutations
Presenter: Mengxi Ge
Session: Poster session 08
182P - Multi-modal artificial intelligence outperforms image-based approaches for mutation prediction from H&E tissue images in colorectal cancer
Presenter: Marc Päpper
Session: Poster session 08